

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Xunfei Healthcare Technology Co., Ltd.

訊飛醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2506)

VOLUNTARY ANNOUNCEMENT ENTERING INTO COOPERATION FRAMEWORK AGREEMENT WITH RICHI HEALTH

This announcement is voluntarily made by Xunfei Healthcare Technology Co., Ltd. (the **“Company”**, together with its subsidiaries, the **“Group”**) for the purpose of providing the shareholders of the Company (**“Shareholders”**) and potential investors with information on the latest business development of the Group.

COOPERATION FRAMEWORK AGREEMENT

On October 14, 2026, the Company entered into a cooperation framework agreement (the **“Cooperation Framework Agreement”**) with Shanghai Rich Health Investment Group Co., Ltd. (上海瑞慈醫療投資集團有限公司) (**“Shanghai Rich Medical”**), an indirect wholly-owned subsidiary of Rici Healthcare Holdings Limited (**“Rici Healthcare”**, a company listed on the Main Board of the Stock Exchange, stock code: 1526, together with its subsidiaries, the **“Rici Healthcare Group”**). The principal terms of the Cooperation Framework Agreement are set out below:

Date: October 14, 2026

Parties: (i) the Company
(ii) Shanghai Rich Medical

Subject Matter: Pursuant to the Cooperation Framework Agreement, the parties agree to cooperate in the following areas:

- (i) the Company authorizes Shanghai Rich Medical to use certain functions of the Company's Xunfei Spark Medical Model, including but not limited to symptom self-assessment, medication inquiry and report interpretation;
- (ii) achieving interconnectivity of user health data, subject to explicit authorization from users; and
- (iii) exploring commercialized health management solutions, including the joint promotion of health management packages and cross-selling of related products and services through medical examination business channels.

INFORMATION ON THE PARTIES

The Group

The Company is a leader in China's artificial intelligence healthcare sector, and is committed to becoming an artificial intelligence-powered medical assistant for every doctor and an artificial intelligence-powered health partner for everyone. Leveraging medical large model technology and the construction of a medical knowledge base, the Company consistently maintains its leading position in medical large models. The Company has created the artificial intelligence-powered Intelligent Assistant product series and the artificial intelligence-powered Health Partner product series to empower governments, hospitals and patients.

Rici Healthcare Group

Rici Healthcare Group is principally engaged in the provision of general hospital services and medical examination services in the People's Republic of China. Headquartered in Shanghai, Rici Healthcare Group is a leading private medical examination provider and a comprehensive medical service provider in the Yangtze River Delta. As of June 30, 2026, Rici Healthcare Group had a business network spanning 28 cities with 1 Class III Grade B general hospital and 80 medical examination centers in operation.

REASONS FOR AND BENEFITS OF ENTERING INTO THE COOPERATION FRAMEWORK AGREEMENT

The Board is of the view that the strategic cooperation with Rici Health is a crucial step for Xunfei Xiaoyi to transition from technical capabilities to service implementation. Medical examinations serve as a natural entry point for health management and represent the most viable scenario for creating a closed-loop system. As a leading force in the private medical examination industry recording millions of visits annually, Rici Health provides Xunfei Xiaoyi with a large-scale validation scenario featuring real, high-frequency, and structured services: AI is embedded into the entire health service chain, from understanding pre-examination needs and providing decision support during examinations to conducting continuous post-examination management. With Rici Health serving as a benchmark for cooperation in private medical examinations, the “AI + Medical Examination” model jointly explored by both parties will evolve into a replicable industry paradigm.

The Board is of the view that entering into the Cooperation Framework Agreement will facilitate the Group in driving the large-scale validation and commercial exploration of AI medical large models and smart health assistant products in medical examination and health management scenarios, thereby enhancing the user experience of health services, and is in the interests of the Company and its Shareholders as a whole.

GENERAL INFORMATION

The Board wishes to emphasize that the cooperation contemplated under the Cooperation Framework Agreement may or may not proceed, and as at the date of this announcement, the parties have not entered into any legally binding agreement in respect of any specific transaction contemplated under the Cooperation Framework Agreement. Should the transactions contemplated under the Cooperation Framework Agreement materialize, the Company will make further announcement(s) in due course in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and other applicable laws and regulations.

By order of the Board
Xunfei Healthcare Technology Co., Ltd.
Dr. Tao Xiaodong
Executive Director

Hong Kong, October 15, 2026

As at the date of this announcement, the Board of the Company comprises: (i) Dr. Tao Xiaodong as executive director; (ii) Dr. Liu Qingfeng, Mr. Zhao Zhiwei and Mr. Duan Dawei as non-executive directors; and (iii) Prof. Wang Yang, Prof. Zhao Huifang and Mr. Tan Ching as independent non-executive directors.